The study of pharmacogenetics and pharmacogenomics focuses on how our genes and complex gene systems influence our response to drugs. Recent progress in clinical therapeutics has led to the discovery of new biomarkers that make it technically easier to identify groups of patients which are more or less likely to respond to individual therapies. The aim is to improve personalised medicine - not simply to prescribe the right medicine, but to deliver the right drug at the right dose at the right time. This textbook brings together leading experts to discuss the latest information on how human genetics impacts drug response phenotypes. It presents not only the basic principles of pharmacogenetics, but also clinically valuable examples that cover a broad range of specialties and therapeutic areas. This textbook is an invaluable introduction to pharmacogenetics and pharmacogenomics for health care professionals, medical students, pharmacy students, graduate students and researchers in the biosciences.
Papildus informācija
This textbook presents the latest information on pharmacogenetics and pharmacogenomics for students, professionals and researchers.
| Contributors |
|
vii | |
| Introduction |
|
xi | |
|
|
|
|
|
|
|
|
|
|
1 Introduction to Population Diversity and Genetic Testing |
|
|
3 | (9) |
|
|
|
|
|
|
|
|
|
2 Genotyping Technologies |
|
|
12 | (9) |
|
|
|
|
|
3 Pharmacokinetics: Absorption, Distribution, Metabolism, Excretion Overview
Chapter |
|
|
21 | (6) |
|
|
|
4 Overview: Adverse Drug Reactions |
|
|
27 | (11) |
|
|
|
5 PharmGKB, a Centralized Resource for Pharmacogenomic Knowledge and Discovery |
|
|
38 | (17) |
|
|
|
|
|
|
|
55 | (11) |
|
|
|
7 Ethical Considerations for Pharmacogenomics: Privacy and Confidentiality |
|
|
66 | (8) |
|
|
|
8 Informed Consent in Pharmacogenomic Research and Treatment |
|
|
74 | (7) |
|
|
|
9 Legal Trends Driving the Clinical Translation of Pharmacogenomics |
|
|
81 | (16) |
|
|
|
Part II Therapeutic Areas |
|
|
|
|
|
97 | (18) |
|
|
|
|
|
11 Pharmacogenetics and Pharmacogenomics of Cardiovascular Disease |
|
|
115 | (10) |
|
|
|
|
|
12 Statin-Induced Muscle Toxicity |
|
|
125 | (11) |
|
|
|
|
|
|
|
|
|
|
|
13 Genomics of the Drug-Induced Long-QT Syndrome |
|
|
136 | (9) |
|
|
|
|
|
|
|
|
|
14 Pharmacogenetics of Diabetes |
|
|
145 | (9) |
|
|
|
|
|
15 Pharmacogenetics-Therapeutic Area-Respiratory |
|
|
154 | (21) |
|
|
|
|
|
16 Pharmacogenomics Associated with Therapy for Acid-Related Disorders |
|
|
175 | (13) |
|
|
|
17 Pharmacogenetics of Rheumatology: Focus on Rheumatoid Arthritis |
|
|
188 | (14) |
|
|
|
|
|
|
|
|
|
18 Pharmacogenetics of Obstetric Therapeutics |
|
|
202 | (15) |
|
|
|
|
|
19 Pharmacogenomics of Psychiatric Drugs |
|
|
217 | (7) |
|
|
|
|
|
224 | (14) |
|
|
|
|
|
21 HIV and Antiretroviral Therapy |
|
|
238 | (11) |
|
|
|
22 Application of Pharmacogenetics and Pharmacogenomics in Pediatrics: What Makes Children Different? |
|
|
249 | (14) |
|
|
|
|
|
23 Fetal and Neonatal Pharmacogenomics |
|
|
263 | |
|
|
Russ Altman is Chairman of the Bioengineering Department and Professor of Bioengineering, Genetics, and Medicine at Stanford University. His primary research interests are in the application of computing technology to basic molecular biological problems of relevance to medicine. David Flockhart is the Harry and Edith Gladstein Chair in Cancer Genomics and Professor of Medicine, Medical Genetics and Pharmacology at the Indiana University School of Medicine in Indianapolis. He is also the Director of the Division of Clinical Pharmacology. His research is focused on clinically relevant applications of pharmacogenetics and drug interactions. David Goldstein is the Richard and Pat Johnson Distinguished University Professor and Director of the Center for Human Genome Variation at Duke University. He is also Professor of Molecular Genetics and Microbiology at Duke. His principal interests include human genetic diversity, the genetics of disease and pharmacogenetics.
